Scinai Immunotherapeutics Azioni (NASDAQ: SCNI)

Ultime notizie per Scinai Immunotherapeutics (NASDAQ:SCNI) Azioni

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/scni-stock-quote/"><strong>SCNI</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Scinai Immunotherapeutics reported earnings per share of -$4.00.</li><li>The company reported revenue of $284,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/scni-stock-earnings-scinai-immunotherapeutics-for-q2-of-2024/">SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024

Scinai Immunotherapeutics reports H1 results

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has secured a $2 million inve...

Scinai Secures $2M Investment Boost

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics has successfully restructured its loan with the European Investm...

Scinai Immunotherapeutics Restructures Debt, Boosts Equity

Scinai Immunotherapeutics regains compliance with Nasdaq listing rule

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has successfully restructured its finances, converting near...

Scinai Immunotherapeutics Back on Track with Nasdaq

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significan...

Scinai Immunotherapeutics Restructures Debt, Eyes Growth

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has struck a significant deal, granting exclusive global ri...

Scinai Immunotherapeutics Licenses Global Rights

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics is set to hold its Annual General Meeting on November 21, 2024, ...

Scinai Immunotherapeutics to Hold Annual Shareholder Meeting

SCNI

Small Cap

Press Releases

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Earnings

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Regains Full Compliance with Nasdaq Listing Requirements

General

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Anitra

Bone Biologics

Bionomics Limited - American Depository Shares

Bionomics

Bio-Path Hldgs

Ensysce Biosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Molecular Templates

NuCana

Oragenics

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Scinai Immunotherapeutics

Notizie

Ultime notizie per Scinai Immunotherapeutics (NASDAQ:SCNI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO